New hope for chronic myelogenous leukemia patients: dasatinib offers better efficacy with shorter treatment.

about

New hope for chronic myelogenous leukemia patients: dasatinib offers better efficacy with shorter treatment.

Item

http://www.wikidata.org/entity/Q42407714

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

New hope for chronic myelogeno ...... ficacy with shorter treatment.

@en

New hope for chronic myelogeno ...... ficacy with shorter treatment.

@nl

type

Item

label

New hope for chronic myelogeno ...... ficacy with shorter treatment.

@en

New hope for chronic myelogeno ...... ficacy with shorter treatment.

@nl

prefLabel

New hope for chronic myelogeno ...... ficacy with shorter treatment.

@en

New hope for chronic myelogeno ...... ficacy with shorter treatment.

@nl

P1476

New hope for chronic myelogeno ...... ficacy with shorter treatment.

@en

P2093

Kazuhito Naka

http://www.w3.org/2001/XMLSchema#string

P2860

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Spotlight on dasatinib in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.

Novel oral transforming growth factor-β signaling inhibitor EW-7197 eradicates CML-initiating cells.

Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia

Targeting survival pathways in chronic myeloid leukaemia stem cells

Pushing the limits of targeted therapy in chronic myeloid leukaemia.

Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial.

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21037/SCI.2016.05.05

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Tatsuo Ichinohe

P577

2016-06-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27488943

http://www.w3.org/2001/XMLSchema#string

P932

4958058

http://www.w3.org/2001/XMLSchema#string